News of Note—CureVac, Bavarian Nordic and more

non
In this week's of news of note, CureVac's CEO is stepping down. (Pixabay)

Here is some other vaccine news of note for the week.

> Even a flu vaccine 20% effective would avert 21 million infections and save 61,000 lives, as long as about 40% of Americans got their shots, a new study led by Yale University researchers found. HealthDay News article

> CureVac’s founder and CEO Ingmar Hoerr, Ph.D., plans to transition to chairman, handing the reins over to current CBO and U.S. subsidiary CEO Daniel Menichella. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Bavarian Nordic announced the FDA has granted orphan drug designation to its cancer vaccine BN-Brachyury for the treatment of chordoma. Release

> British firm Scancell raised £8.7 million in a public offering to help advance the development of its cancer vaccines. Labiotech article

The Scripps Research Institute landed a $12 million grant from the Bill & Melinda Gates Foundation to study vaccines that can neutralize many strains of malaria and influenza. Release

> Emergent BioSolutions reported $117.8 million in revenues from the first quarter, hurt by delays in the delivery of BioThrax and ACAM2000. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.